SER
AMEXSerina Therapeutics Inc.
Price$2.07+0.03 (+1.47%)
02:30 PM07:45 PM
News · 26 weeks580%
2026-02-012026-07-26
Mix3390d
- Insider16(48%)
- SEC Filings9(27%)
- Other6(18%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRSerina Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceHUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to request a meeting. About the POZ Platform™ Serina’s proprietary POZ technology is based on a synthetic, water-soluble, low viscosity polymer called poly(2-oxazoline). The POZ platform is engineered to provide gr
- INSIDERSEC Form 4 filed by Director Simon Farrell4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 3 filed by new insider Simon Farrell3 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol - - Company expects to provide a further update following completion of the Safety Monitoring Committee review – HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b regist
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Appoints Farrell Simon to its Board of DirectorsHUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees. "We are pleased to welcome Dr. Simon to Serina’s Board of Directors," said Steve Ledger, Chief Executive Officer of Serina Therapeutics. "Farrell has been a key leader at Trevi as the company has significantly expanded its enterprise value and raised substantial capital to advance i
- PRSerina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseData Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 - Dosing of additional patients in Cohort 1 is underway at sites in the US and Australia - Company is on track to complete Cohort 1 enrollment and dosing ahead of previously disclosed guidance of the end of the third quarter of 2026 – HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registratio
- INSIDERDirector Brannan Stephen K. bought $2,030 worth of shares (1,000 units at $2.03) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- ANALYSTBTIG Research initiated coverage on Serina Therapeutics with a new price targetBTIG Research initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $8.00
- PRGannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 ProgramHUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology. Under the agreement, Gannet BioChem will support development activities for SER-252, Serina's investigational therapy for advanced Parkinson's disease. SER-252 recently received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application, enabling the advancement of the program into clinical development. The collaboration brings together Seri
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERDirector Venkatesan Jay bought $1,048 worth of shares (589 units at $1.78) and converted options into 224,152 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Bailey Gregory converted options into 8,437,472 shares, increasing direct ownership by 6,663% to 8,564,382 units (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Brannan Stephen K.4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilson Karen J4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Marshall Richard Peter4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Wilson Karen J bought $17,750 worth of shares (10,100 units at $1.76) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form EFFECT filed by Serina Therapeutics Inc.EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERChief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Ledger Steven A4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Curhan Gregory S4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Moreadith Randall4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
SER FAQ
6 questionsWhere does SER stock trade?
Serina Therapeutics Inc. (SER) is listed on AMEX.What sector and industry is SER in?
Serina Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Serina Therapeutics Inc. go public?
Serina Therapeutics Inc. (SER) completed its IPO in 2018.What are analysts saying about SER?
Serina Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $800.00 price target on 2026-07-01. Recent price targets range from $800.00 to $1500.00.What companies are similar to SER?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SER side-by-side with any of them on Quantisnow.How can I track SER on Quantisnow?
Quantisnow aggregates Serina Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SER to receive live email and push alerts on every new disclosure.